Aptus Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Aptus Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,118	Closed	-$225K	–	1840
2026 Q1	$225K	Sell	8,118 -1,698	-17%	-$43.6K	﹤0.01%	972
2025 Q4	$213K	Buy	+9,816	New	+$194K	﹤0.01%	1014
2025 Q3	–	Sell	-10,077	Closed	-$114K	–	1648
2025 Q2	$114K	Buy	10,077 +52	+0.5%	+$564	﹤0.01%	1054
2025 Q1	$101K	Buy	+10,025	New	+$108K	﹤0.01%	1008

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Aptus Capital Advisors's ROIV Position: Q2 2026 in Review

Aptus Capital Advisors sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 8,118 shares — an estimated $225K sold.

Aptus Capital Advisors first reported a position in ROIV in Q1 2025 and held it in 4 quarters. The position peaked at $225K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Aptus Capital Advisors reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Aptus Capital Advisors sold 8,118 Roivant Sciences shares in Q2 2026, an estimated $225K.
Aptus Capital Advisors first reported a position in Roivant Sciences in Q1 2025 and held it in 4 quarters.
Aptus Capital Advisors's Roivant Sciences position peaked at $225K in Q1 2026.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.